Liminal Biosciences
Develops small-molecule therapeutics for metabolic, inflammatory and fibrotic diseases through GPCR pathways
Highlights
- New on EvolcAdded 2026-11-01
About Liminal Biosciences
Liminal BioSciences is a development-stage biopharmaceutical company discovering and developing small-molecule therapeutics that modulate G protein-coupled receptor pathways. Its programs target metabolic, inflammatory and fibrotic diseases.
The company operates through its wholly owned subsidiary, Caledon Bioscience, and is privately held by Structured Alpha LP. It has a registered office in Belleville, Ontario, and talent hubs in Quebec and the United Kingdom.
The company was founded in 2015 and is headquartered in Altrincham, United Kingdom.
Product: Drug discovery and development programs for small-molecule therapeutics targeting GPCR pathways.
Jobs at Liminal Biosciences
Leadership
- Bruce Pritchard · Chief Executive OfficerSource: company website
More biotech & pharma companies
Lindus Health
Clinical development of in-licensed drug assets for biotech and pharma partners, run on an AI clinical trial platformNew on EvolcRemote-friendlyMacomics
Macrophage-directed drugs that clear large disease protein complexes, first targeting IgA nephropathy patientsNew on EvolcMaxion Therapeutics
Engineered protein therapeutics for ion channel- and GPCR-driven diseasesNew on EvolcMC2 Therapeutics
Topical dermatology products, prescription and DermoCosmetic, for psoriasis and itchy, dry or sensitive skinNew on EvolcMdbiologics
UK healthcare company with separate websites for healthcare professionals and members of the publicYoung companyNew on EvolcMedherant
Clinical-stage pharma developing the TEPI Patch transdermal platform, starting with a testosterone patch for postmenopausal womenNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Contact Form 7High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Marketing & advertising
- X PixelMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Privacy & consent
- OneTrustHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.